According to incomplete statistics from Meibo Capital, in February 2024, the total number of China's pharmaceutical BD transactions was...11Pen, whereinCross-border Asset Purchase4Pen,Cross-border Asset Sale5Pen,Transactions within China2Pen.

1. Brii Biosciences and VBI Reach AgreementBRII-179, etc.Intellectual Property Transfer, Licensing, and Asset Acquisition of 3 Projects‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍

2. Shanghai Hezhou Pharmaceutical Co., Ltd. Obtains an α-Isotope Radioligand Drug Targeting PSMA

     On February 20, 2024, Shanghai Hezhou Pharmaceutical Co., Ltd. announced an exclusive strategic partnership with ARTBIO, Inc. (hereinafter referred to as "ARTBIO").According to the agreement signed by both parties, Shanghai Hezhou Pharmaceutical Co., Ltd. will act as the exclusive strategic partner of ARTBIO, utilizing the AlphaDirect™ radionuclide separation and purification technology to produce lead-212 (²¹²Pb) radionuclides. This innovative technology will fill a gap in the international market.At the same time, Shanghai Hezhou Pharmaceutical Co., Ltd. will obtain the development and commercialization rights of AB001 in Greater China (including mainland China, Hong Kong, Macao, and Taiwan). AB001 is an α radionuclide radioligand drug targeting prostate-specific membrane antigen (PSMA), which has now entered the clinical development stage. In addition, Shanghai Hezhou Pharmaceutical Co., Ltd. will have the right to use the AlphaDirect™ technology to develop proprietary intellectual property ²¹²Pb radionuclide radioligand drugs for undisclosed targets worldwide. Both parties can also introduce each other's products in the future to accelerate the global commercialization process of the products.

3. Zai Lab ObtainsBristol-Myers Squibb's Opdivo and Yervoy China 10-Provinces Sales Agency Rights‍‍

On February 20, 2024, Bristol-Myers Squibb and Zai Lab reached a strategic cooperation. Zai Lab will be responsible for promoting Opdivo (PD-1 Monoclonal Antibody "O Drug"And Eversevo (CTLA-4 Monoclonal Antibody "Y Drug"。Specifically including Yunnan, Guizhou, Guangxi, Inner Mongolia, Xinjiang, Gansu, Ningxia, Qinghai, Hebei, and Shanxi, among 10 provinces.

4. Jiangsu Nhwa Pharmaceutical Co.,Ltd. and TevaAusted®Strategic Cooperation Reached

On February 22, 2024, Teva (TEVA) and Jiangsu Nhwa Pharmaceutical Co., Ltd. held the signing ceremony for their strategic cooperation and the co-commercialization of Austedo® in China at the Nhwa Technology Building. According to the cooperation agreement, Teva granted Jiangsu Nhwa Pharmaceutical Co., Ltd. the exclusive commercialization rights of Austedo® in mainland China. This product is used to treat chorea associated with Huntington's disease and tardive dyskinesia in adults. This collaboration marks an important step in the partnership between the two parties in the field of neuropsychiatry.

1. Luye Pharma GroupRivastigmineSign a cooperation agreement with Myung In Pharm‍

    On February 5, 2024, Luye Pharma Group signed a cooperation agreement with Myung In Pharm, a South Korean pharmaceutical company, granting Myung In Pharm the commercial rights in South Korea for its exclusive new drug – a twice-weekly rivastigmine transdermal patch. The rivastigmine transdermal patch (2 times/week) is used to treat symptoms of mild to moderate Alzheimer's disease.Rivastigmine is a first-line medication for the treatment of mild to moderate Alzheimer's disease. The rivastigmine transdermal patch (2 times/week) offers an innovative drug delivery method, administering the drug through the skin twice a week, which reduces the frequency of use and can improve patient compliance. Compared with oral formulations, the rivastigmine transdermal patch (2 times/week) is absorbed by the body through the skin, providing greater convenience for patients with swallowing difficulties and potentially reducing the incidence of gastrointestinal adverse reactions such as nausea and vomiting.

2. Biocytogen Announces Antibody Evaluation and Selection Agreement with Gilead Sciences

    On February 20, 2024, Biocytogen announced that it had entered into an antibody evaluation and selection agreement with Gilead Sciences. The agreement grants Gilead access to Biocytogen's fully human antibody library, developed for a wide range of drug targets, to evaluate antibodies for relevant targets. During the three-year nomination period, Gilead will nominate multiple targets of interest and assess corresponding antibodies, with the option to select specific antibodies for the development of therapeutic products on a global scale. Under the terms of the agreement, Biocytogen will receive an upfront payment enabling Gilead to evaluate specific antibodies against selected targets. For each nominated target and selected antibody, Biocytogen is entitled to receive option exercise fees, development, regulatory, and sales milestone payments, as well as single-digit royalties on net sales.

3. HBM Pharma Enters into Antibody-Drug Conjugate Discovery Collaboration Agreement with BOOSTIMMUNE

2024February 27,Harbour BioMed's Wholly-Owned Subsidiary, Nona Biosciences, Enters into ADC Discovery Collaboration Agreement with Boostimmune, Inc. to Establish Strategic Partnership for Developing ADC Therapies. Under the agreement, Nona Biosciences will provide Boostimmune with its dual, double light chain (H2L2) HarbourMice platform to develop ADC therapies targeting novel antigens. The HarbourMice platform can generate fully human monoclonal antibodies in dual, double light chain (H2L2) and heavy-chain only (HCAb) formats. Immune cell engagers (HBICE) developed based on HCAb antibodies can achieve anti-tumor efficacy that traditional drug combination therapies cannot. HarbourMice, HBICE, and the single B-cell cloning platform together form a unique and efficient next-generation innovative therapeutic antibody R&D engine.

4. Prometheus Announces Strategic Collaboration with Bitterroot Bio

On February 27, 2024, Primus Bio announced a multi-year, multi-product strategic collaboration with Bitterroot Bio in the United States to jointly develop bispecific protein-based therapeutics capable of modulating the immune system and regulating inflammatory responses, aiming to treat various cardiovascular diseases.This collaboration aims to leverage the dual strengths of Primus Bio's leading capabilities in multi-antibody protein drug design, construction, and development, alongside Bitterroot Bio's expertise in cardiovascular biology, pathology, and translational medicine, with the hope of bringing revolutionary clinical treatment options to patients with atherosclerosis and other life-threatening cardiovascular diseases.

5. BMS and RingRNA Biotech Reach Feasibility Study Collaboration on Circular RNA Technology

    2On February 29, 2024, Huanma Biotech announced a feasibility study collaboration with Bristol-Myers Squibb (“BMS”) to explore the feasibility of applying circular RNA technology in a specific therapeutic area. This collaboration will fully leverage Huanma Biotech's proprietary circular RNA technology.StatusThe RNA technology platform, together with Bristol-Myers Squibb's extensive expertise and accumulation in the pharmaceutical field, deepens the understanding within the industry of cyclic...StatusUnderstanding of RNA Technology Drug Translation.Circular RNA is a closed circular molecule, which, as a special type of non-coding RNA with unique structural properties, can exist independently without relying on proteins and is unaffected by exonucleases. It is widely present in animal and plant cells and regulates gene expression.

1. Hutchmed Licenses 2 New Drugs to Inmagene Biopharmaceuticals

2024On February 2, HUTCHMED announced that it has exercised the options related to the licensing of two drug candidates, IMG-007 and IMG-004, under the strategic cooperation terms signed with Inmagene Biopharmaceuticals.According to the terms of the agreement, for each candidate drug, HUTCHMED is entitled to receive up to $95 million in development milestone payments and up to $135 million in commercial sales milestone payments, as well as a share of annual net sales in the high single-digit to double-digit percentages after commercialization. The total value of the collaboration agreement can reach up to $227.5 million.

2. China Medical System Obtains Exclusive Licensing Rights for Innovative First-Line Phosphorus-Lowering Drug "Vifor"

    February 2, 2024China Medical System Holdings Limited Announces the Signing of a Novation Agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. ("VFMCRP") and Winner Group regarding Sucroferric Oxyhydroxide Chewable Tablets (Vifury) ("Product").Weikang Investment and VFMCRP entered into a licensing agreement ("Licensing Agreement") for the product on June 28, 2023. Under the Licensing Agreement, Weikang Investment obtained the exclusive rights to register, import, promote, distribute, use, and sell the product in mainland China, the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan ("Territory"). The term of the Licensing Agreement commences from its effective date until the fifteenth anniversary of the first commercial sale of the product within the Territory. Upon expiration of the aforementioned term, the Licensing Agreement may be automatically renewed for an additional ten years based on specific conditions stipulated in the Licensing Agreement. Thereafter, unless the parties reach a new agreement, the Licensing Agreement will terminate upon expiration.According to the replacement agreement, Weijian Investment replaces its aforementioned rights and responsibilities for the product with Kangzhe Pharmaceutical's wholly-owned subsidiary.

    Virtually Better, Inc.The first iron-based, non-calcium phosphate binder approved by China NMPA for marketing, filling the gap in phosphorus-lowering treatment for Chinese CKD pediatric patients aged 12 to 18 with CKD stages 4-5 or receiving dialysis.

In February 2024, due to the Chinese New Year and other reasons, the total number of transactions significantly decreased compared to 30 transactions in January. Most License-out deals did not disclose upfront payments or other transaction amounts. Strategic cooperation and joint development costs were the main features of this month's transactions in the Chinese market.BMS Collaborates with Zai Lab, Camsun Pharmaceuticals and Winner Pharmaceuticals Alternate Commercialization Rights, Continuous Strengthening of Commercial Capabilities through Corporate Synergy。Chinese pharmaceutical companies seize international opportunities to benefit patients worldwide。

This article is reprinted from Meibai Capital

Disclaimer

This article is a reprint and is intended solely for sharing purposes, and does not represent the views of the platform. The copyrights of images, articles, fonts, etc., belong to the original authors. If there is any infringement, please inform us, and we will handle it promptly.

------------------------------

「Long Press」Add Xiao Da via QR code「Join the group」

Explore Market Frontiers with More Industry Partners

Aimeida Medical Consulting

IMED Consulting (Beijing) Co., Ltd., established in April 2014, is a professional consulting service provider in the pharmaceutical industry. The company is committed to deeply integrating industrial policy research with real-world data mining, gaining insights into the impact of industry policies on the market, providing forward-looking market analysis through professional research, and offering comprehensive solutions for market access after the launch of corporate products.